Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
Introduction Tyrosine kinase inhibitors (TKIs) have significantly improved the progression-free survival (PFS) of metastatic non-small cell lung cancer (NSCLC) with oncogene mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) compared with systemic therapy alone...
Guardado en:
Autores principales: | Sadhna Kannan, Kumar Prabhash, Anil Tibdewal, JaiPrakash Agarwal, Naveen Mummudi, Vanita Noronha, Vijay Patil, Nilendu Purandare, Amit Janu, Rajiv Kaushal |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/92f32865e1284db5868d83e018827764 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Management of VEGFR-Targeted TKI for Thyroid Cancer
por: Tomohiro Enokida, et al.
Publicado: (2021) -
HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021) -
Author Correction: Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Yen-Ju Chen, et al.
Publicado: (2021) -
TAJUK RENCANA HARIAN KOMPAS DAN MEDIA INDONESIA MENGUPAS NASIB TKI: ANALISIS PERBANDINGAN STRUKTUR TEKS
por: Yosi Wulandari
Publicado: (2013) -
TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity
por: Hayato Ogura, et al.
Publicado: (2017)